Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 1 to 10 of 25 matches

Category 5 - DIAGNOSTIC IMAGING SERVICES

Capital Sensitivity Measure for Diagnostic Imaging Equipment

Category 5 - DIAGNOSTIC IMAGING SERVICES

Group I2 - Computed Tomography (CT)

Category 5 - DIAGNOSTIC IMAGING SERVICES

Group I4 - Nuclear Medicine Imaging

Category 3 - THERAPEUTIC PROCEDURES

15559

15559 - Additional Information

Item Start Date:
01-May-2006
Description Start Date:
01-May-2006
Schedule Fee Start Date:
01-Nov-2012

Group
T2 - Radiation Oncology
Subgroup
5 - Computerised Planning

DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 2 COMPLEXITY where:

(a)    dosimetry for a two phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, two planning target volumes and one organ at risk defined in the prescription; or

(b)    dosimetry for a one phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, one planning target volume and two organ at risk dose goals or constraints defined in the prescription; or

(c)    image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 1 complexity.


All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images



Fee: $866.55 Benefit: 75% = $649.95 85% = $783.15

(See para TN.2.3 of explanatory notes to this Category)

Category 3 - THERAPEUTIC PROCEDURES

15562

15562 - Additional Information

Item Start Date:
01-May-2006
Description Start Date:
01-May-2006
Schedule Fee Start Date:
01-Nov-2012

Group
T2 - Radiation Oncology
Subgroup
5 - Computerised Planning

DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 3 COMPLEXITY - where:

(a)    dosimetry for a three or more phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, three planning target volumes and one organ at risk defined in the prescription; or

(b)    dosimetry for a two phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, and

        (i) two planning target volumes; or

        (ii) two organ at risk dose goals or constraints defined in the prescription.

or

(c)    dosimetry for a one phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, one planning target volume and three organ at risk dose goals or constraints defined in the prescription;

or

(d)    image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 2 complexity.


All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images



Fee: $1,120.75 Benefit: 75% = $840.60 85% = $1,037.35

(See para TN.2.3 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61523

61523 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
22-Dec-2005
Schedule Fee Start Date:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61529

61529 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
22-Dec-2005
Schedule Fee Start Date:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61538

61538 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-Jul-2011
Schedule Fee Start Date:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R)

Bulk bill incentive



Fee: $901.00 Benefit: 75% = $675.75 85% = $817.60

Category 5 - DIAGNOSTIC IMAGING SERVICES

61541

61541 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-Jul-2011
Schedule Fee Start Date:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61553

61553 - Additional Information

Item Start Date:
01-Jul-2018
Description Start Date:
01-Jul-2011
Schedule Fee Start Date:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R)

Bulk bill incentive



Fee: $999.00 Benefit: 75% = $749.25 85% = $915.60

(See para IN.0.19 of explanatory notes to this Category)

Results 1 to 10 of 25 matches


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change